236 related articles for article (PubMed ID: 23555840)
1. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
3. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
4. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
6. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
7. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
10. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
14. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2.
Riina HA; Burkhardt JK; Santillan A; Bassani L; Patsalides A; Boockvar JA
Interv Neuroradiol; 2012 Jun; 18(2):127-32. PubMed ID: 22681725
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
16. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Eminowicz GK; Raman R; Conibear J; Plowman PN
J Laryngol Otol; 2012 Jan; 126(1):79-82. PubMed ID: 22004800
[TBL] [Abstract][Full Text] [Related]
18. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
19. Is there a Role for Bevacizumab in Non-Glial Tumors?
Trevisan E; Bertero L; Magistrello M; Rudà R; Soffietti R
Curr Drug Targets; 2015; 16(7):684-8. PubMed ID: 25808649
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
